Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy
By Ben Glickman
Tyra Biosciences said it received Rare Pediatric Disease Designation from regulators for its potential treatment for a form of dwarfism.
The Carlsbad, Calif.-based biotechnology company said Thursday the U.S. Food and Drug Administration had granted the designation to TYRA-300 as a potential treatment of achondroplasia.
The company said achondroplasia is the most common form of dwarfism and has limited available therapies.
Tyra plans to submit an Investigational New Drug application to the FDA in the second half of 2024, which would allow the company to begin a Phase 2 clinical trial examining dose cohorts.
RPD designation is given by the FDA to potential drugs to treat rare serious or life-threatening diseases which primarily affect children.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
February 01, 2024 18:05 ET (23:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth